Radiotherapy-PCV versus radiotherapy-temozolomide for IDH-mutant anaplastic astrocytoma: a retrospective multicentre analysis of the French POLA cohort.

CONCLUSIONS: RT + PCV significantly improved PFS compared to RT + TMZ for IDH-mutant AA. However, RT + TMZ was better tolerated.
IMPLICATIONS FOR PRACTICE: In the absence of fully conducted randomized trials comparing PCV to TMZ in adjuvant treatment after RT for the management of IDH-mutant AA and a similar level of evidence, these two chemotherapies are both equally recommended in international guidelines. Our study in a national cohort of IDH-mutant AA defined according the 2016 WHO classification shows for the first time that the RT + PCV regimen significantly improves PFS in comparison to the RT + TMZ regimen. Even if at the time of analysis the difference in OS was not significant, this result provides new evidence for the debate about the chemotherapy regimen to prescribe in adjuvant treatment to RT for WHO 2016 IDH-mutant AA.
PMID: 33524191 [PubMed - as supplied by publisher]

Source: The Oncologist - February 1, 2021 Category: Cancer & Oncology Authors: Esteyrie V, Dehais C, Martin E, Carpentier C, Uro-Coste E, Figarella-Branger D, Bronniman C, Pouessel D, Ciron DL, Ducray F, Moyal EC, POLA Network Tags: Oncologist Source Type: research